ImmuneCyte  is a multilingual, clinical-stage biopharmaceutical firm dedicated to the study and creation of alternative cell and gene medicines, such as CAR-NK, mononuclear, and T cells with chimeric antigen receptors, for the treatment of cancer, vascular, orthopaedic, and age-related illnesses. They have developed technological cell-based genetreatments on this platform to treat severe cases of b-thalassemia, a fatal blood genetic condition.

ImmuneCyte, Inc.

Org chart

Similar companies